Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-γ

Gene Therapy

Volumn 7, Issue 8, 2000, Pages 707-713

  Lei, H ^a   Ju, D W ^a   Yu, Y ^a   Tao, Q ^a   Chen, G ^a   Gu, S ^a   Hamada, H ^b   Cao, X ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Foundation for the Promotion of Cancer Research (Japan)   (Japan)

Author keywords

Gene therapy; IFN ; Immunotherapy; M CSF; Macrophages; Melanoma

Indexed keywords

B7 ANTIGEN; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NITRIC OXIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE THERAPY; GENETIC TRANSDUCTION; LUNG CANCER; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0034060430     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301162     Document Type: Article

References (36)

1. Yoshida R, Yoneda Y, Kuriyama M, Kubota T. IFN-γ and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment. J Immunol 1999; 163: 148-154.
2. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998; 64: 419-426.
3. Killion JJ, Fidler IJ. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Pharmacol Ther 1998; 78: 141-154.
4. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183-1187.
5. Celluzzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160: 3081-3085.
6. Ashley DM et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186: 1177-1782.
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
8. Yoshioka H et al. Transformation of rat glioma cells with the M-CSF gene inhibits tumorigenesis in vivo. J Neuro-oncol 1998; 40: 197-204.
9. Sakurai T et al. Effect of macrophage colony-stimulating factor (M-CSF) on mouse immune responses in vivo. Immunopharmacol Immunotoxicol 1998; 20: 79-102.
10. Fixe P, Praloran V. M-CSF: haematopoietic growth factor or inflammatory cytokine? Cytokine 1998; 10: 32-37.
11. Heike Y et al. M-CSF gene transduction in multidrug-resistant human cancer cells to enhance anti-P-glycoprotein antibody-dependent macrophage-mediated cytotoxicity. Int J Cancer 1993; 54: 851-857.
12. Wolff DJ, Gribin BJ. Interferon-gamma-inducible murine macrophage nitric oxide synthase: studies on the mechanism of inhibition by imidazole agents. Arch Biochem Biophys 1994; 311: 293-299.
13. Martin JH, Edwards SW. Interferon-gamma enhances monocyte cytotoxicity via enhanced reactive oxygen intermediate production. Absence of an effect on macrophage cytotoxicity is due to failure to enhance reactive nitrogen intermediate production. Immunology 1994; 81: 592-597.
14. Marodi L et al. Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest 1993; 91: 2596-2601.
15. Goldberg M, Belkowski LS, Bloom BR. Regulation of macrophage growth and antiviral activity by interferon-gamma. J Cell Biol 1989; 109: 1331-1340.
16. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 1999; 11: 76-81.
17. Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-gamma. An update. Ann NY Acad Sci 1998; 856: 22-32.
18. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 1997; 75: 202-207.
19. Kimball ES, Kovacs E, Clark MC, Schneider CR. Activation of cytokine production and adhesion molecule expression on THP-1 myelomonocytic cells by macrophage colony-stimulating factor in combination with interferon-gamma. J Leukoc Biol 1995; 58: 585-594.
20. Morse MA et al. Phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5: 1331-1338.
21. Parmiani G, Colombo MP, Melani C, Arienti F. Cytokine gene transduction in the immunotherapy of cancer. Adv Pharmacol 1997; 40: 259-307.
22. Pardoll DM. Cancer vaccines. Nature Med 1999; 4: 525-531.
23. Ballow M, Nelson R. Immunopharmacology: immunomodulation and immunotherapy. JAMA 1997; 278: 2008-2017.
24. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TCP-beta, and prostaglandin E2. J Immunol 1994; 153: 1674-1686.
25. Aoe T, Okamoto Y, Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 1995; 181: 1881-1886.
26. Dullens HF, Den Otter W. Therapy with allogeneic immune peritoneal cells. Cancer Res 1974; 34: 1726-1730.
27. Hennemann B et al. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother 1998; 45: 250-256.
28. Eymard JC et al. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur J Cancer 1996; 32: 1905-1911.
29. Dorsch M et al. Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression. Eur J Immunol 1993; 23: 186-190.
30. Abe J et al. Antitumor effect induced by granulocyte/ macrophage colony-stimulating factor gene-modified tumor vaccination comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 1995; 121: 587-593.
31. Kanai F et al. In vivo gene therapy for alpha fetoprotein producing hepatocellular carcinoma by adenovirus mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461-465.
32. Ju DW, Cao X, Arces B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther 1997; 4: 139-144.
33. Ju DW, Wang BM, Cao X. Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity. J Cancer Res Clin Oncol 1998; 124: 683-689.
34. Cao X et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998; 161: 6238-6244.
35. Cao X et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Gene Therapy 1998; 5: 1130-1136.
36. Abe K et al. Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production. Cancer Immunol Immunother 1998; 45: 225-233.